ND03
Cytokine Profiles Across DR2 Haplotype and Vitamin D Status in the Intermountain Multiple Sclerosis Project

Thursday, May 25, 2017
B2 (New Orleans Convention Center)
Laura E Baldassari, MD, MHS , Neurology, University of Utah, Salt Lake City, UT
Hanieh Seraj, MS , Neurology, University of Utah, Salt Lake City, UT
C. Dee Husebye, BS , Neurology, University of Utah, Salt Lake City, UT
M. Mateo Paz Soldan, MD, PhD , Neurology, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT
Thomas Martins, MS , ARUP Institute for Clinical Research, Salt Lake City, UT
Noel G Carlson, PhD , Department of Neurobiology and Anatomy, University of Utah, Salt Lake City, UT
John W Rose, MD , Neurology, University of Utah School of Medicine, Salt Lake City, UT
Laura E Baldassari, MD, MHS , Neurology, University of Utah, Salt Lake City, UT



Background: Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system linked to autoimmunity. The DR2 haplotype has been identified as a genetic risk factor for MS, and may be regulated in part by vitamin D. This gene-environment interaction is of great interest, as vitamin D deficiency has been associated with both the development and progression of MS. We sought to determine whether differential pro- and anti-inflammatory cytokine expression could identify biomarkers and help elucidate the mechanism of this complex interaction. Preliminary data on a subset of these patients has been previously presented. 

Objectives: To investigate the relationship between DR2 haplotype, vitamin D status, and cytokine expression in MS in the Intermountain MS Project. 

Methods: The Intermountain MS Project is a cohort study intended to identify biomarkers and genes in MS. Baseline patient serum samples were analyzed to: quantify concentrations of pro- and anti-inflammatory cytokines via Multiplexed Cytokine Assay, obtain DR2 haplotype information, and determine seasonally adjusted vitamin D concentrations. 

Results: We report clinical characteristics of MS patients (n=797) and concentrations of pro- and anti-inflammatory cytokines stratified by DR2 haplotype and vitamin D status (normal versus insufficient/deficient). MS patients who were vitamin D insufficient or deficient were found to have statistically significantly higher levels of CD40-ligand, IL-1-beta, IL-2-receptor, and IL-12, and lower levels of IFN-gamma, IL-4, and IL-13 compared to those with normal vitamin D level. No cytokine expression was found to be statistically significantly different between DR2 positive versus negative patients. IL-12 and IL-13 expression were significantly decreased in DR2-positive patients who were vitamin D insufficient/deficient compared to normal (p = 0.022 and 0.0002, respectively), but this difference did not exist among DR2-negative patients (p = 0.055 and 0.510, respectively). 

Conclusions: This study presents further analysis of the potential mechanism for a gene-environment interaction in MS; namely, the differential expression of IL-12 and Il-13 among DR2-positive patients who were vitamin D insufficient or deficient. The underlying immunology and potential implications of these results will be discussed.